Conversely, it has been reported that increased levels of DRP1 induced by ABT737, an inhibitor of antiapoptotic BCL-2/BCL-XL, promote mitochondrial fission, leading to apoptosis and mitophagy in ovarian cancer cells resistant to cisplatin. Here, BCL2 is linked to ovarian cancer.